Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study

BACKGROUND. This study compared the efficacy of regorafenib and trifluridine/tipiracil (TFTD) in patients with metastatic colorectal cancer (mCRC) who are refractory to standard chemotherapy, because despite their clinical approval, it still remains unclear which of these two drugs should be used as...

Descripción completa

Detalles Bibliográficos
Autores principales: Moriwaki, Toshikazu, Fukuoka, Shota, Taniguchi, Hiroya, Takashima, Atsuo, Kumekawa, Yusuke, Kajiwara, Takeshi, Yamazaki, Kentaro, Esaki, Taito, Makiyama, Chinatsu, Denda, Tadamichi, Satake, Hironaga, Suto, Takeshi, Sugimoto, Naotoshi, Enomoto, Masanobu, Ishikawa, Toshiaki, Kashiwada, Tomomi, Sugiyama, Masahiko, Komatsu, Yoshito, Okuyama, Hiroyuki, Baba, Eishi, Sakai, Daisuke, Watanabe, Tomoki, Tamura, Takao, Yamashita, Kimihiro, Gosho, Masahiko, Shimada, Yasuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Gastrointestinal Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759812/
https://www.ncbi.nlm.nih.gov/pubmed/28894015
http://dx.doi.org/10.1634/theoncologist.2017-0275

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759812/
https://www.ncbi.nlm.nih.gov/pubmed/28894015
http://dx.doi.org/10.1634/theoncologist.2017-0275

Ejemplares similares